{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:50:08Z","timestamp":1790607008077,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA054274"],"award-info":[{"award-number":["DA054274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA049539"],"award-info":[{"award-number":["DA049539"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006324","name":"American Psychological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.neuropharm.2022.109290","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T03:34:48Z","timestamp":1665545688000},"page":"109290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Usage of L-type calcium channel blockers to suppress drug reward and memory driving addiction: Past, present, and future"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2948-493X","authenticated-orcid":false,"given":"Hitoshi","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper A.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109290_bib1","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1038\/s41386-018-0080-2","article-title":"The L-type calcium channel blocker, isradipine, attenuates cue-induced cocaine-seeking by enhancing dopaminergic activity in the ventral tegmental area to nucleus accumbens pathway","volume":"43","author":"Addy","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109290_bib2","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1523\/JNEUROSCI.0280-07.2007","article-title":"Combined activation of L-type Ca2+ channels and synaptic transmission is sufficient to induce striatal long-term depression","volume":"27","author":"Adermark","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nn2054","article-title":"CaMKII: a biochemical bridge linking accumbens dopamine and glutamate systems in cocaine seeking","volume":"11","author":"Anderson","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib4","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/s41380-019-0513-2","article-title":"Cocaine- and stress-primed reinstatement of drug-associated memories elicit differential behavioral and frontostriatal circuit activity patterns via recruitment of L-type Ca(2+) channels","volume":"25","author":"Bavley","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109290_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2006.03.017","article-title":"Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists","volume":"537","author":"Biala","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pbb.2007.12.005","article-title":"Calcium-dependent mechanisms of the reinstatement of nicotine-conditioned place preference by drug priming in rats","volume":"89","author":"Biala","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109290_bib7","first-page":"497","article-title":"Effects of calcium channel antagonists on the reinforcing properties of morphine, ethanol and cocaine as measured by place conditioning","volume":"47","author":"Biala","year":"1996","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","article-title":"Dopamine in motivational control: rewarding, aversive, and alerting","volume":"68","author":"Bromberg-Martin","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109290_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.neuron.2004.10.013","article-title":"State-dependent calcium signaling in dendritic spines of striatal medium spiny neurons","volume":"44","author":"Carter","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109290_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1152\/jn.1998.79.1.82","article-title":"Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances","volume":"79","author":"Cepeda","year":"1998","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"'Rejuvenation' protects neurons in mouse models of Parkinson's disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109290_bib12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.biopsych.2005.09.024","article-title":"Microinjection of the L-type calcium channel antagonist diltiazem into the ventral nucleus accumbens shell facilitates cocaine-induced conditioned place preferences","volume":"59","author":"Chartoff","year":"2006","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109290_bib13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.conb.2012.06.004","article-title":"Pavlovian valuation systems in learning and decision making","volume":"22","author":"Clark","year":"2012","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tins.2014.02.002","article-title":"Illicit dopamine transients: reconciling actions of abused drugs","volume":"37","author":"Covey","year":"2014","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/mp.2015.84","article-title":"L-type Ca(2)(+) channel blockade with antihypertensive medication disrupts VTA synaptic plasticity and drug-associated contextual memory","volume":"21","author":"Degoulet","year":"2016","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109290_bib16","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.neubiorev.2013.02.010","article-title":"From the ventral to the dorsal striatum: devolving views of their roles in drug addiction","volume":"37","author":"Everitt","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109290_bib17","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/00001756-199707070-00019","article-title":"Dopamine facilitates striatal EPSPs through an L-type Ca2+ conductance","volume":"8","author":"Galarraga","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2022.109290_bib18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10550490290087983","article-title":"Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits","volume":"11","author":"Gottschalk","year":"2002","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.neuropharm.2022.109290_bib19","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1523\/JNEUROSCI.2519-09.2009","article-title":"Robust pacemaking in substantia nigra dopaminergic neurons","volume":"29","author":"Guzman","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","article-title":"Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1","volume":"468","author":"Guzman","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109290_bib21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.neuron.2009.05.011","article-title":"Burst-timing-dependent plasticity of NMDA receptor-mediated transmission in midbrain dopamine neurons","volume":"62","author":"Harnett","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109290_bib22","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1523\/JNEUROSCI.17-09-03334.1997","article-title":"D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca2+ conductance","volume":"17","author":"Hernandez-Lopez","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib23","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1038\/ncomms5481","article-title":"Modest CaV1.342-selective inhibition by compound 8 is beta-subunit dependent","volume":"5","author":"Huang","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2022.109290_bib24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0306-4522(02)00267-1","article-title":"Firing modes of midbrain dopamine cells in the freely moving rat","volume":"114","author":"Hyland","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109290_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002130050575","article-title":"Isradipine prevents global and regional cocaine-induced changes in brain blood flow: a preliminary study","volume":"136","author":"Johnson","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109290_bib26","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0893-133X(99)00116-5","article-title":"Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans","volume":"22","author":"Johnson","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109290_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pnpbp.2004.08.014","article-title":"Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals","volume":"29","author":"Johnson","year":"2005","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109290_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/S1461145704005036","article-title":"Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects","volume":"8","author":"Johnson","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002130051007","article-title":"Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study","volume":"144","author":"Johnson","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109290_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.amjhyper.2005.01.020","article-title":"Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: results from two human laboratory studies","volume":"18","author":"Johnson","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.neuropharm.2022.109290_bib31","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/ncomms2149","article-title":"CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease","volume":"3","author":"Kang","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2022.109290_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neuron.2015.08.037","article-title":"Dopamine prediction errors in reward learning and addiction: from theory to neural circuitry","volume":"88","author":"Keiflin","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109290_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0091-3057(92)90363-K","article-title":"Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice","volume":"41","author":"Kuzmin","year":"1992","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109290_bib34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0953-816X.2003.03110.x","article-title":"Suppressing calcium\/calmodulin-dependent protein kinase II activity in the ventral tegmental area enhances the acute behavioural response to cocaine but attenuates the initiation of cocaine-induced behavioural sensitization in rats","volume":"19","author":"Licata","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib35","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1152\/jn.00486.2004","article-title":"L-type calcium channels: the low down","volume":"92","author":"Lipscombe","year":"2004","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","article-title":"The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson's disease","volume":"59","author":"Liss","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/pharmrev.120.000245","article-title":"L-type calcium channel blockers: a potential novel therapeutic approach to drug dependence","volume":"73","author":"Little","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109290_bib38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1152\/jn.00757.2013","article-title":"Cav1.2 and Cav1.3 L-type calcium channels regulate dopaminergic firing activity in the mouse ventral tegmental area","volume":"112","author":"Liu","year":"2014","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1152\/jn.1992.67.1.145","article-title":"Responses of monkey dopamine neurons during learning of behavioral reactions","volume":"67","author":"Ljungberg","year":"1992","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1476-5381.1994.tb17068.x","article-title":"Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones","volume":"113","author":"Mercuri","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib41","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nature03015","article-title":"Computational roles for dopamine in behavioural control","volume":"431","author":"Montague","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109290_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02316861","article-title":"Effects of nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans","volume":"105","author":"Muntaner","year":"1991","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109290_bib43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1113\/jphysiol.1993.sp019742","article-title":"Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in Guinea-pig substantia nigra pars compacta neurones","volume":"466","author":"Nedergaard","year":"1993","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejphar.2004.03.024","article-title":"Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure","volume":"491","author":"Oliveto","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib45","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.neuropharm.2011.03.010","article-title":"Natural rewards, neuroplasticity, and non-drug addictions","volume":"61","author":"Olsen","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109290_bib46","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1523\/JNEUROSCI.3327-04.2005","article-title":"G-protein-coupled receptor modulation of striatal CaV1.3 L-type Ca2+ channels is dependent on a Shank-binding domain","volume":"25","author":"Olson","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib47","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0165-0173(97)00039-8","article-title":"Burst firing in midbrain dopaminergic neurons","volume":"25","author":"Overton","year":"1997","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2022.109290_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuroscience.2014.07.032","article-title":"Generating bursts (and pauses) in the dopamine midbrain neurons","volume":"282","author":"Paladini","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109290_bib49","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1523\/JNEUROSCI.1478-05.2005","article-title":"Dopamine cells respond to predicted events during classical conditioning: evidence for eligibility traces in the reward-learning network","volume":"25","author":"Pan","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0014-2999(90)90537-G","article-title":"Nimodipine inhibits cocaine-induced dopamine release and motor stimulation","volume":"176","author":"Pani","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-2999(90)94128-K","article-title":"Calcium receptor antagonists modify cocaine effects in the central nervous system differently","volume":"190","author":"Pani","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib52","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0361-9230(91)90022-C","article-title":"The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine","volume":"26","author":"Pani","year":"1991","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109290_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106013","article-title":"Isradipine enhancement of virtual reality cue exposure for smoking cessation: rationale and study protocol for a double-blind randomized controlled trial","volume":"94","author":"Papini","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.neuropharm.2022.109290_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0014-2999(93)90551-R","article-title":"Verapamil suppresses d-amphetamine-induced place preference conditioning","volume":"240","author":"Pucilowski","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0893-133X(94)00080-J","article-title":"Isradipine suppresses amphetamine-induced conditioned place preference and locomotor stimulation in the rat","volume":"12","author":"Pucilowski","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109290_bib56","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1523\/JNEUROSCI.19-15-06348.1999","article-title":"L-Type Ca(2+) channels are essential for glutamate-mediated CREB phosphorylation and c-fos gene expression in striatal neurons","volume":"19","author":"Rajadhyaksha","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib57","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1523\/JNEUROSCI.0612-04.2004","article-title":"L-type Ca2+ channels mediate adaptation of extracellular signal-regulated kinase 1\/2 phosphorylation in the ventral tegmental area after chronic amphetamine treatment","volume":"24","author":"Rajadhyaksha","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib58","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1126\/science.1102384","article-title":"Addiction as a computational process gone awry","volume":"306","author":"Redish","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109290_bib59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1037\/1064-1297.13.4.319","article-title":"Effects of repeated-dose isradipine on the abuse liability of cocaine","volume":"13","author":"Roache","year":"2005","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109290_bib60","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1098\/rstb.2008.0093","article-title":"Review. The incentive sensitization theory of addiction: some current issues","volume":"363","author":"Robinson","year":"2008","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib61","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00002826-199408000-00007","article-title":"Nimodipine pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence","volume":"17","author":"Rosse","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF00179925","article-title":"Cocaine-calcium channel antagonist interactions","volume":"93","author":"Rowbotham","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109290_bib63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1530-0277.1998.tb03686.x","article-title":"Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans","volume":"22","author":"Rush","year":"1998","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2022.109290_bib64","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41593-018-0191-4","article-title":"Dopamine neurons create Pavlovian conditioned stimuli with circuit-defined motivational properties","volume":"21","author":"Saunders","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib65","doi-asserted-by":"crossref","first-page":"13562","DOI":"10.1523\/JNEUROSCI.2315-11.2011","article-title":"Cav1.2 L-type Ca(2)(+) channels mediate cocaine-induced GluA1 trafficking in the nucleus accumbens, a long-term adaptation dependent on ventral tegmental area Ca(v)1.3 channels","volume":"31","author":"Schierberl","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib66","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1152\/physrev.00023.2014","article-title":"Neuronal reward and decision signals: from theories to data","volume":"95","author":"Schultz","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109290_bib67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuroscience.2017.07.049","article-title":"Distinctive changes of L-type calcium channels and dopamine receptors in the dorsomedial and dorsolateral striatum after the expression of habitual cocaine-seeking behavior in rats","volume":"370","author":"Shen","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109290_bib68","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0006-8993(98)01231-1","article-title":"Nifedipine blocks apamin-induced bursting activity in nigral dopamine-containing neurons","volume":"817","author":"Shepard","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109290_bib69","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/mol.108.049981","article-title":"Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms","volume":"75","author":"Sinnegger-Brauns","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109290_bib70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nature19845","article-title":"A basal ganglia circuit for evaluating action outcomes","volume":"539","author":"Stephenson-Jones","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109290_bib71","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1126\/science.1160873","article-title":"Reward-predictive cues enhance excitatory synaptic strength onto midbrain dopamine neurons","volume":"321","author":"Stuber","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109290_bib72","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1021\/jm500263v","article-title":"New 5-unsubstituted dihydropyridines with improved CaV1.3 selectivity as potential neuroprotective agents against ischemic injury","volume":"57","author":"Tenti","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109290_bib73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuron.2012.09.023","article-title":"Dopaminergic modulation of synaptic transmission in cortex and striatum","volume":"76","author":"Tritsch","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109290_bib74","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamapsychiatry.2022.1240","article-title":"Association of drug cues and craving with drug use and relapse: a systematic review and meta-analysis","volume":"79","author":"Vafaie","year":"2022","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109290_bib75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pbr.2015.08.004","article-title":"Animal models of drug relapse and craving: from drug priming-induced reinstatement to incubation of craving after voluntary abstinence","volume":"224","author":"Venniro","year":"2016","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109290_bib76","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/npp.2013.75","article-title":"Conditioned contribution of peripheral cocaine actions to cocaine reward and cocaine-seeking","volume":"38","author":"Wang","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109290_bib77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-neuro-072116-031109","article-title":"Neural circuitry of reward prediction error","volume":"40","author":"Watabe-Uchida","year":"2017","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109290_bib78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbr.2008.10.030","article-title":"Synaptic plasticity in the basal ganglia","volume":"199","author":"Wickens","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109290_bib79","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3390\/cells9092045","article-title":"Calcium, bioenergetics, and Parkinson\u2019s disease","volume":"9","author":"Zampese","year":"2020","journal-title":"Cells"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:43Z","timestamp":1758439183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":79,"alternative-id":["S0028390822003495"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109290","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usage of L-type calcium channel blockers to suppress drug reward and memory driving addiction: Past, present, and future","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109290"}}